Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases.

Genome Med · 2013 · PMC3971342 · PMID 24373343

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

nearly significantP = 0.06so close (0.05 < p ≤ 0.1)

Interestingly, even though evidence for an association of baseline IGFBP1 with CHD risk was weak, there was a nearly significant association ( P = 0.06) of risk with change from baseline to year 1 in IGFBP1 concentration, and the OR for treatment was null (OR = 0.96) after controlling for IGFBP1 change.

also in 3,279 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.